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Castleman disease (CD) is a rare lymphoproliferative disorder which in its 
multicentric form results in systemic inflammatory symptoms, 
lymphadenopathy, and multi-organ involvement. Interleukin-6 (IL-6) is 
implicated in CD pathogenesis, inducing B-cell proliferation, 
hypergammaglobulinanemia, and acute phase responses1. Mediastinal 
lymphadenopathy is common but other pulmonary manifestations are 
infrequent2,3. Multiple treatments have been reported1; unsurprisingly an 
evolving role of biological therapies is emerging.  
 
We present the clinical course of a 33-year old female of Chinese descent with 
systemic upset and cystic lung disease due to lymphoid interstitial pneumonia 
(LIP), subsequently diagnosed as manifestations of idiopathic HIV-negative HHV-
8-negative multicentric plasma cell type Castleman disease. We describe her 
clinical course as influenced by advent of a variety of immunomodulatory 
therapies. 
 
In 2009 our patient presented with malaise, weight-loss, cough and 
breathlessness, with normocytic anaemia, hypergammaglobulinaemia (diffuse 
increase, no paraproteinaemia), hypoalbuminaemia, elevated CRP at 81mg/L 
(normal range<10mg/L) and ESR 129mm/hr (normal range: 1-12mm/hr). 
Thoracic CT (Fig 1A) demonstrated multiple thin-walled cysts and mediastinal 
lymphadenopathy. Tuberculosis was excluded. Lung biopsy confirmed LIP with 
interstitial infiltration by plasma cells and lymphocytes. Autoimmune disease 
and immunodeficiency are associated with LIP4, but our patient was HIV 
negative, hepatitis B and C negative, functional/diagnostic antibodies were 
within reference range. Typically, LIP responds to high-dose corticosteroids, but 
1.5mg/kg prednisolone (75mg daily) resulted in only transient, limited symptom 
improvement. Cough and systemic upset recurred on dose-reduction, with ESR 
persistently >100mm/hr.  
 
Given lack of treatment response alternative diagnoses were explored. 
Hypergammaglobulinaemia was notably persisting and rising (IgG being 60g/L 
(normal range: 6-16g/L) in 2010 rising to 68.2g/L by March 2011, with 
additional IgA and M rises). Bone marrow aspirate demonstrated excess plasma 
cells (up to 50% of the cellularity; Fig. 1B), but no clonal lymphocyte population 
or lymphoma evident. Whole body CT demonstrated persistent thoracic 
lymphadenopathy and worsening lung involvement but no solid organ 
abnormality or non-thoracic adenopathy. Repeat autoantibody and infection 
screen was negative. Literature review highlighted an association of CD with LIP 
in patients of Asian ancestry, a feature not readily evident in the Western 
literature4. Lymph node biopsy via mediastinoscopy demonstrated substantial 
plasmacytic infiltrate (Fig. 1C) consistent with the plasma cell variant of CD. Both 
HIV and HHV-8 infection are associated with CD, but serum and lymph node 
tissue demonstrated no HHV-8 infection. Serum free IL-6 levels were not 
elevated.  
 
Her condition deteriorated with requirement for home oxygen, ongoing weight-
loss and IgG rising to 72.9g/L. With IL-6 implicated in CD pathogenesis, the anti-
human IL-6 receptor monoclonal antibody Tocilizumab (350mg intravenous 
monthly infusion) was commenced. Mixed treatment response was seen with 
only transient symptomatic improvement, mixed immunoglobulin response with 
partial improvement in IgG, only transient fall in IgA and no improvement in IgM 
levels (Fig. 1D), no effect on ESR (Fig. 1E) and limited CRP reduction (Fig. 1F). 
Dosage was increased to twice monthly infusions with no additional benefit. 
Respiratory disease continued to worsen.  
 
Given lack of elevation in free IL-6 and response to IL-6 blockade in our patient 
we elected to focus on the hyperglobulinaemia, and accordingly used the 
proteasome inhibitor Bortezomib (6 cycles of two-weekly subcutaneous 
injections with dexamethasone; commenced April 2014) to directly target 
plasma cell immunoglobulin synthesis. Initial improvements were evident with 
reduction in all immunoglobulins, normalization of CRP and fall in ESR (Fig. 1D-
F), improved respiratory function and nutritional status with normalization of 
weight and albumin. Inflammatory indices began to rise during the treatment 
course and disease activity recurred shortly after Bortezomib cessation. 
 
B cell targeting was re-attempted via anti-human CD20 monoclonal antibody 
Rituximab (two 1000mg intravenous infusions; June 2015), in combination with 
further Bortezomib (6 cycles with dexamethasone).  Combination therapy 
resulted in sustained symptomatic improvement, lung disease stabilization, and 
marked improvement in all inflammatory indices (Fig. 1D-F). However recent 
rising inflammatory indices off therapy suggest further courses will be required. 
 
Aside from the complex diagnostic challenge presented by this case and the 
importance of considering clinical disease in the setting of ethnicity, her 
management highlights evolving therapies against Castleman disease mediated 
immune dysregulation. Despite a small prospective study reporting sustained 
efficacy (median treatment duration of 65-weeks) of tocilizumab in multicentric 
HIV-negative CD5, we achieved only transient response – perhaps commensurate 
with the low circulating IL-6 levels. Neutralizing antibodies to tocilizumab have 
been implicated in lack of efficacy, although typically infrequently occur with this 
agent.  
 
Reports of Bortezimib inducing sustained remission in CD exist6. Small 
prospective studies in HIV-positive CD demonstrate Rituximab maintains 
sustained response either alone or following chemotherapy7. We are unaware of 
any previous reports of Bortezomib with Rituximab in HIV-negative CD, a 
therapeutic combination that we have found to result in effective sustained 
amelioration of resistant systemic CD manifestations. 
 
Although we have focused on therapeutic targeting of B cell dysregulation and 
hyperglobulinaemia, we are open to consideration of alternative immune 
pathways8 with comprehensive studies potentially elucidating a complex 
immunopathogenesis in our patient.  
 
 
Figure Legend: 
Fig. 1 – Radiological, pathological and immunological manifestations in a 
case of multicentric Castleman Disease 
(A) High-resolution CT scan demonstrating multiple thin-walled cysts. (B) Bone 
marrow trephine stained for CD138. (C) Mediastinal lymph node biopsy stained 
with hematoxylin and eosin staining. (D) Serum immunoglobulin levels during 
the course of treatment. IgG normal range: 6-16g/L. IgM normal range: 0.4 – 
2.4g/L. IgA normal range: 0.8 – 4.0 g/L.  (E) Erythrocyte sedimentation rate 
(ESR) during course of treatment. Normal range: 1-12mm/hr. (F) C-reactive 
protein (CRP) during course of treatment. Normal range <10mg/L. (D-F) Boxes 
relate to treatment periods with Toculizumab, Bortezomib and Rituximab (with 
corresponding key shown to right of figure). 
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